NCT06383520RecruitingEarly phase 1
Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 14 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a diagnostic study. Patients were recruited from patients with clinically suspected or confirmed hepatocellular carcinoma and healthy volunteers were recruited for PET/or PET/CT imaging targeting a GPC3-specific probe (in the case of 68Ga-NOTA-aGPC3-scFv) , to observe the reaction of volunteers and patients after injection of drugs, to evaluate the pharmacokinetics in vivo and the efficacy of diagnosis and staging, and to perform PET CT imaging in patients with contraindications. General Information, clinical data, blood routine, liver and renal function, and other imaging data were collected. The final diagnosis was based on the histopathology of biopsy or surgical specimens.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 22 Apr 2024
- Start date
- 30 Sept 2023
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06383520
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 100
- From 30 Sept 2023 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 6: Individuals who are unable to complete PET/MR or PET/CT examinations (including inability to lie flat, claustrophobia, radiation phobia, etc.)
Other illness
- 3: Acute systemic diseases and electrolyte disorders
- 4: Patients who are known to be allergic to GPC3 imaging agents or synthetic excipients
Lab values
- 5: Fasting blood glucose levels exceeding 11.0 mmol/L before injection of 18F-FDG
Other
- 1: Pregnant or lactating patients
- 2: The patient or their legal representative is unable or unwilling to sign the informed consent form
- 7: Researchers believe that compliance is poor or there are other unfavorable factors for participating in this experiment
Who the study is looking for
- 1: Voluntarily participate and the person or their legal representative can sign an informed consent form
- 2: Adult patients (18 years of age or older), regardless of gender
- 3: Patients with newly diagnosed hepatocellular carcinoma with high clinical suspicion or confirmation (supporting evidence including imaging data and histopathologic examination, etc.) who agree to undergo histopathologic examination (if not performed prior to imaging) or/and 18F-FDG PET imaging
- 4: Healthy volunteer
- 5: Patients with a history of hepatocellular carcinoma, remission and recurrence after treatment
- 6: Willing and able to follow schedule visits, treatment plans and laboratory tests
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China, Hubei Province Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
Related publications
- Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study.Eur J Nucl Med Mol Imaging · 2026 · PMID 41688850
This page is information, not medical advice. Discuss any trial with your doctor.